Multiple myeloma and kidney disease
DOI:
https://doi.org/10.12775/JEHS.2022.12.08.089Keywords
multiple myeloma, myeloma cast nephropathy, bortezomib, RANKLAbstract
Abstract
Background: Multiple myeloma is a clonal plasma cell neoplasm which affects 1% of all malignancies. In this article we reviewed epidemiology, symptoms with particular attention to renal failure and its manifestation in multiple myeloma (MM).
Material and methods: This paper was based on medical articles collected in PubMed from 2001 to 2022, medical websites and books. The research has been done by looking through key words such as: „multiple myeloma”, „myeloma cast nephropathy”, „bortezomib”, „RANKL”
Results: Multiple myeloma has indolent course and many patients present renal disorders at the moment of diagnosis. The use of novel therapies can reverse renal failure.
Conclusions: Treatment of the patients with MM and kidney disease is challenging for health care professionals. Doctors have to adjust treatment to provide the best therapeutic effects.
References
Giannopoulos K. et al.; Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2021
Grosicki S; Multiple myeloma with renal insufficiency as a therapeutic challenge Sebastian Grosicki; Acta Haematologica Polonica Volume 46, Issue 2, April 2015,p. 80-85
Wojciechowska U. et al.; Nowotwory złośliwe w Polsce w 2018; Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie, Państwowy Instytut Badawczy, Warszawa 2020
Praca zbiorowa (2021) Interna Szczeklika 2021, pod red. Piotra Gajewskiego, Medycyna Praktyczna; Kraków 2020; p. 1891-1899
Dhodapkar MV.; MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood. 2016 Dec 8;128(23):2599-2606. doi: 10.1182/blood-2016-09-692954. Epub 2016 Oct 13. PMID: 27737890; PMCID: PMC5146746.
Weiss BM et al.; A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 2009 May 28;113(22):5418-22. doi: 10.1182/blood-2008-12-195008. Epub 2009 Feb 20. PMID: 19234139; PMCID: PMC2689043.
Joshua DE et al.; Biology and therapy of multiple myeloma. Med J Aust. 2019 May;210(8):375-380. doi: 10.5694/mja2.50129. Epub 2019 Apr 23. PMID: 31012120.
Vickrey E.; Multiple myeloma: vague symptoms can challenge diagnostic skills. JAAPA. 2008 Nov;21(11):19-22. doi: 10.1097/01720610-200811000-00005. PMID: 19105542.
Praca zbiorowa Onkologia Podręcznik dla studentów i lekarzy, pod red. Jacka Jassema i Radzisława Kordka; Gdańsk 2019; p. 326
Oyajobi BO.; Multiple myeloma/hypercalcemia. Arthritis Res Ther. 2007;9 Suppl 1(Suppl 1):S4. doi: 10.1186/ar2168.
Joshua D et al.; Biology and therapy of multiple myeloma. Med J Aust. 2019 May;210(8):375-380. doi: 10.5694/mja2.50129.
Leung N, Nasr SH.; Myeloma-related kidney disease. Adv Chronic Kidney Dis. 2014 Jan;21(1):36-47. doi: 10.1053/j.ackd.2013.08.009.
Heher EC et al.; Kidney disease and multiple myeloma. Clin J Am Soc Nephrol. 2013 Nov;8(11):2007-17. doi: 10.2215/CJN.12231212.
Sathick I.J et al.; Cast nephropathy vs Acute Tubular Necrosis in newly diagnosed Multiple Myeloma: a comparative study; Clinical Lymphoma, Myeloma and Leukemia; vol. 15, Sep 01, 2015
Katagiri D et al.;. Multiple myeloma and kidney disease. ScientificWorldJournal. 2013 Oct 27;2013:487285. doi: 10.1155/2013/487285.
Abbott KC, Agodoa LY.; Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol. 2001 Sep;56(3):207-10. PMID: 11597035.
Eleutherakis-Papaiakovou V et al.; Greek Myeloma Study Group. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma. 2007 Feb;48(2):337-41. doi: 10.1080/10428190601126602.
Ryšavá R. Renal failure in multiple myeloma and its treatment. Vnitr Lek. 2020 Fall;66(7):425-431. English. PMID: 33380121.
Kumar S. et al.; Renal response in real-world carfilzomib- vs bortezomib-treated patients with relapsed or refractory multiple myeloma. Blood Adv. 2021 Jan 26;5(2):367-376. doi: 10.1182/bloodadvances.2019001059.
Kanellias N. et al.; Management of multiple myeloma bone disease: impact of treatment on renal function. Expert Rev Hematol. 2018 Nov;11(11):881-888. doi: 10.1080/17474086.2018.1531702.
Charakterystyka produktu leczniczego kwasu zoledronowego (5ml/4mg)
Bridoux F. et al.; International Kidney and Monoclonal Gammopathy Research Group. Management of acute kidney injury in symptomatic multiple myeloma. Kidney Int. 2021 Mar;99(3):570-580. doi: 10.1016/j.kint.2020.11.010.
https://www.mp.pl/pacjent/leki/subst.html?id=5831 (access on: 23.08.2022)
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Natalia Zarankiewicz, Katarzyna Kosz, Martyna Zielińska, Klaudia Remjasz, Aleksandra Kuchnicka, Julia Kuchnicka, Klaudia Sapuła, Jakub Aleksandrowicz, Wojciech Siedlecki
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 380
Number of citations: 0
